Duyuru • Mar 27
Gemina Laboratories Ltd. Announces Delisting from the Canadian Securities Exchange Gemina Laboratories Ltd. ("Gemina" or the "Company") announced that the Canadian Securities Exchange (the "CSE") has approved is application to voluntarily delist its common shares from trading on the CSE. The Company obtained the approval of its disinterested shareholders at its annual general and special meeting held on March 13, 2026. The Company expects the delisting to become effective at the close of trading on 27th March, 2026. Following the delisting, the Company will remain a reporting issuer in the provinces of Alberta, British Columbia and Ontario and will continue to comply with its continuous disclosure obligations under applicable securities laws in those jurisdictions. The decision to delist from the CSE was made after careful consideration of the Company's current operational needs, trading volumes, and the costs associated with maintaining a listing. The Company believes that the delisting is in the best interests of the Company and its shareholders. Board Change • Jan 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Chair of Clinical Advisory Board Michael Shannon was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • Dec 31
Gemina Laboratories Ltd. announced that it expects to receive $3 million in funding Gemina Laboratories Ltd. announced a private placement of secured, non-convertible debentures for gross proceeds of a minimum of $1,000,000 and maximum of $3,000,000 on December 30, 2025. Each debenture will consist of a $1,000 principal amount and the payment of the principal and premium, if any, of and interest on, the debentures will be secured by a first priority security interest against the company's intellectual property. The Debentures will mature on the date that is twelve months from the date of closing of the offering and accrue interest at a rate of 18% per annum, which will be compounded monthly, and payable at the maturity date. The company may prepay the principal amount of the Debentures at any time prior to the Maturity Date at a price equal to 105% of the principal amount of the debentures, plus accrued and unpaid interest thereon. The company may close the offering in one or more tranches, up until January 15, 2026 or on such other date as determined by the Company. The Offering is also subject to other customary conditions, including but not limited to, the receipt of all necessary approvals of applicable securities regulatory authorities. Duyuru • Dec 24
Gemina Laboratories Ltd., Annual General Meeting, Feb 13, 2026 Gemina Laboratories Ltd., Annual General Meeting, Feb 13, 2026. Location: british columbia, vancouver Canada New Risk • Dec 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended April 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$465k free cash flow). Shares are highly illiquid. Negative equity (-CA$4.4m). Earnings have declined by 2.9% per year over the past 5 years. Revenue is less than US$1m (CA$11k revenue, or US$7.9k). Market cap is less than US$10m (CA$9.95m market cap, or US$7.23m). Minor Risk Latest financial reports are more than 6 months old (reported April 2025 fiscal period end). New Risk • Nov 30
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$12.3m (US$8.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$465k free cash flow). Shares are highly illiquid. Negative equity (-CA$4.4m). Earnings have declined by 2.9% per year over the past 5 years. Revenue is less than US$1m (CA$11k revenue, or US$7.8k). Market cap is less than US$10m (CA$12.3m market cap, or US$8.77m). New Risk • Jun 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$4.4m). Earnings have declined by 5.0% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$74.2m market cap, or US$54.2m). Duyuru • Nov 14
Gemina Laboratories Ltd. announced that it expects to receive CAD 7 million in funding Gemina Laboratories Ltd. announced a non-brokered private placement that it will issue up to 9,333,333 common shares in the capital of the company at a price of CAD 0.75 per share for the gross proceeds of up to CAD 7,000,000 on November 13, 2024. The securities issued under the offering will be subject to a statutory hold period in Canada expiring four months and one day from the date of issuance. New Risk • Oct 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Shares are highly illiquid. Negative equity (-CA$2.7m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$33.6m market cap, or US$24.9m). Duyuru • Mar 19
Gemina Laboratories Ltd. announced that it has received CAD 0.91 million in funding On March 18, 2024, Gemina Laboratories Ltd closed the transaction. The company has raised gross proceeds of CAD 910,000 of unsecured convertible notes. All securities issued pursuant to the Private Placement are and will be subject to a four month hold period from the date of issue, expiring July 19, 2024, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Duyuru • Mar 16
Gemina Laboratories Ltd., Annual General Meeting, May 13, 2024 Gemina Laboratories Ltd., Annual General Meeting, May 13, 2024. Duyuru • Feb 24
Gemina Laboratories Ltd. announced that it expects to receive CAD 1 million in funding Gemina Laboratories Ltd announced a non brokered private placement to issue 10% unsecured convertible notes for the gross proceeds of CAD 1,000,000 on February 22, 2024. The Notes will be unsecured and have a maturity date of 12 months from the date of issuance, unless earlier converted in accordance with the terms of the Note. At the option may be converted into common shares at a price per Common Share equal to of the Note holder, any principal amount of CAD 0.50 or in the event the Company completes an equity financing prior to the Maturity Date the Late Conversion Price. The Note holder may elect to convert the outstanding Principal into Common Shares at any time prior to the Maturity Date. Interest on the Notes will accrue at a rate of 10% per annum, payable in cash on the Maturity Date or in the case of conversion of the entire Principal, at the time of conversion. The Note holder may elect to have the Interest repaid in cash or converted into Common Shares at the applicable Conversion Price, in accordance with the terms of the Note and by providing the Company with written notice of such election. All securities issued in connection with the Private Placement will be subject to a four-month hold period from the date of issue under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. New Risk • Jan 02
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$670k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.7m free cash flow). Negative equity (-CA$670k). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$39.6m market cap, or US$29.9m). Duyuru • Dec 31
Gemina Laboratories Ltd. Announces the Resignation of Rob Porter as Director and President Gemina Laboratories Ltd. announced the Dr. Rob Porter has stepped down from the board and resigned as President. Dr. Porter will continue as Managing Director of RAPIvD and will focus on its continued growth. New Risk • Jun 25
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$72k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.6m free cash flow). Shares are highly illiquid. Negative equity (-CA$72k). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (CA$35.3m market cap, or US$26.7m). Duyuru • Jun 07
Gemina Laboratories Ltd. Laboratories and ReadyGo Diagnostics Limited Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in Saliva Gemina Laboratories Ltd. announced significant technical results from its collaboration with ReadyGo Diagnostics Ltd. This represents the first step of Gemina's move into molecular diagnostics adding further diagnostic capability to compliment their lateral flow programme. Results from a collaboration which began in January 2023, Gemina and ReadyGo are proud to announce the successful feasibility of detecting Mycobacterium Tuberculosis ("MTB") in a saliva matrix using the ReadyGo GEO platform. This breakthrough in MTB detection paves the way for affordable testing which will have the potential to significantly impact MTB eradication efforts in countries such as India, Indonesia, and other affected regions worldwide. The feasibility of utilizing saliva as a sample for the detection of Mycobacterium tuberculosis through a molecular diagnostic test has been successfully demonstrated. MTB, commonly referred to as "Tuberculosis", is a highly infectious airborne disease caused by bacteria that affects the lungs, and was responsible for more than 10 million global infections in 2021, causing 1.6 million deaths. Alarmingly, an estimated 4 million infections (2 out of every 5 cases) remain undiagnosed and untreated, enhancing disease control efforts. Diagnosis in low- to middle-income countries, where MTB is most prevalent, typically relies on sm microscopy using sputum samples. However, these tests have significant limitations, particularly in remote areas and when diagnosing certain patient populations such as children and the elderly, who struggle to produce sputum. This innovative solution will provide results within 30 minutes, anywhere, at an affordable cost. Following the successful feasibility stage, the team anticipates introducing a compact laboratory instrument retailing for less than $1000, with a per-test cost of $5, enabling field testing near patients. Duyuru • May 18
Gemina Laboratories Ltd. Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement Gemina Laboratories Ltd. announced that its patented chemistry for Antibody Immobilization allows for a massive reduction in antibody usage when used in lateral flow assay (LFA) diagnostic tests. This represents the confirmation of a major technical milestone on the LFA format for Gemina. The Antibody Immobilization Platform allows for the reduction of test line antibody requirements by 75% vs. standard physisorption, without impacting limit-of-detection. Gemina's Antibody Immobilization Platform creates a bridge (the Gemina Bridge) between a sensor surface and the antibodies stuck on that surface for target capture. Use of the Gemina Bridge results in optimized antibody usage and increased target capture activity per unit area of sensor surface. Therefore, use of the Gemina Bridge imparts both significant performance advantages and significant manufacturing advantages with LFA tests. The industry standard antibody immobilization technique on nitrocellulose used in LFAs - non-specific physisorption, results in only 5-20% of the antibodies deposited on a sensor being "active" or capable of target capture. The Gemina Bridge rescues this lost antibody activity, meaning much less antibody is required to deliver the same test performance. Laboratory Study: This massive reduction in antibody requirements was thoroughly demonstrated on the lateral flow assay test line with a COVID-19 rapid antigen test developed by Gemina Labs at the RAPIvD laboratories in Sharnbrook, UK. Instead of striping the antibodies directly onto the nitrocellulose (NC) strip, the Gemina Bridge is first stripped down to form a closely-packed monolayer, onto which the antibodies form a dense secondary layer with four times higher target capture activity than standard antibody-only test lines. Modeling Study: Dr. Robert Davies, an independent surface chemist expert, specializing in lateral flow assay development, was engaged by Gemina Laboratories to model the adsorption of the Gemina Antibody Immobilization Bridge to nitrocellulose, in comparison to optimal close packing of non-specifically adsorbed IgG antibodies. Calculations support the creation of four times more antibody immobilization sites per unit of surface area with the Gemina Bridge, as highlighted in the above-linked white paper. In summary, the Gemina Antibody Immobilization Platform acts as a bridge between a sensor surface, in this instance the nitrocellulose test strip in a lateral flow assay, and the antibody used for target capture. Modeling data and internal experimental results indicate that use of the Gemina Bridge increases the density of active antibodies on the test strip by four times versus standard immobilization methods, meaning 75% less antibody is needed with the Gemina Bridge to achieve the same performance as a standard test. This represents a massive savings in antibody consumption during test fabrication. Duyuru • Jan 26
Gemina Laboratories Ltd. Announces Board Changes Gemina Laboratories Ltd. announced the appointment of Dr. Bola Grace to the Board of Directors. Dr. Grace brings extensive leadership experience in the biotech/healthcare industry to the Board, having provided strategic, commercial and technical direction on many complex programmes, delivering numerous diagnostic products to the consumer marketplace. With a career that started in research and development at Unipath, she went on to hold a Lead Scientist role at Alere before becoming Head of R&D for the global leader in reproductive health testing, Swiss Precision Diagnostics (SPD), a company jointly owned by Abbott Laboratories and Proctor and Gamble. Dr. Grace is a passionate believer in inclusive, user-centric design, not least because of its impact on healthcare equity. She holds a prestigious visiting professorship in this field with the UK's Royal Academy of Engineering. Dr. Grace has always succeeded in balancing her private sector career with her academic interests. Beyond her current visiting professorship with the Royal Academy of Engineering, she previously held a 3-year visiting faculty position at Kings College London and a 9-year engagement with University College London (UCL), initially with the Elizabeth Garrett Anderson Institute for Women's Health, which became a visiting faculty position with UCL's Global Business School for Health. She has Bachelor and Master's degrees in biomedical sciences and molecular biology, and a Ph.D from UCL in population health and epidemiology. She also holds an executive MBA from Cambridge University. She is a fellow of the Royal Society of Public Health and a Fellow of the Chartered Management Institute. With Dr. Grace's appointment to the Board, the Company also announced that Dr. James Tansey has resigned his directorship of Gemina. James will continue to serve the Company as an advisor. Duyuru • Jan 07
Gemina Laboratories Ltd. Completes Influenza A/B Diagnostic Test Prototype Gemina Laboratories Ltd. announced the completion of its influenza A/B rapid test prototype. The company announced its intention to develop an influenza diagnostic in second quarter of 2022, using the company's unique chemistry platform. Influenza A/B: Demand for tests for influenza and other common illnesses has been growing significantly as health care providers seek to distinguish between diseases with common symptoms. In the post-pandemic era, consumers are also demanding greater control over their health status, creating substantial global demand for low-cost diagnostic tools that can be self-administered. After an extensive antibody screening program, Gemina Laboratories, in partnership with RAPIvD, has completed the development of an influenza A/B rapid test prototype (the Gemina Benchmark Test) for internal benchmarking studies to further demonstrate the performance improvements imparted by the Gemina chemistry platform. The Gemina Benchmark Test is designed using the traditional Lateral Flow Assay ("LFA") format commonly found in the rapid COVID tests used throughout the pandemic. The Gemina Benchmark Test has been shown to reliably detect multiple strains of whole influenza A and influenza B viruses in artificial nasal fluid-spiked samples on a single test strip with no cross-reactivity between flu A and B. The Benchmark will now enter the optimization phase, followed by pre-clinical performance evaluation with patient samples. Once performance evaluation is complete, the Gemina Benchmark Test will be put through a series of head-to-head performance evaluation studies against the same test built using Gemina's proprietary immobilization chemistry. This will be a true direct comparison between its proprietary LFA design and the industry standard LFA design. The resultant data will provide a direct measure of the improvements imparted by the Gemina technology in comparison to standard LFAs. Indeed, preliminary comparative studies utilizing the Gemina immobilization chemistry indicate the potential to reduce antibody usage by 6-8 times, while maintaining equivalent sensitivity to the traditional design. Since the majority of LFA tests use expensive antibodies to capture the virus and allow for detection on the test strip, this potential large reduction in antibody use represents a substantial benefit in terms of both cost reduction and improved supply chain security. The next steps for the further integration of the Gemina chemistry platform into its panel of upcoming diagnostic products will be provided in the CEO's strategy update to be released in January 2023. Duyuru • Dec 21
Gemina Laboratories Ltd. Appoints Michael Shannon as Chair of Clinical Advisory Board Gemina Laboratories Ltd. announced Dr. Michael Shannon has been appointed to constitute and Chair the Company's Clinical Advisory Board. Dr. Shannon is one of Canada's pre-eminent public health leaders. He spent 31 years in the Canadian Forces, retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Subsequently, he was appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. Later he served as an Audit Principal and Senior Medical Advisor to the Canadian Auditor General and then accepted responsibilities for rebuilding the Emergency Medical Response System within the newly formed Public Health Agency of Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully conducted in Toronto. Outside of public service, Dr Shannon has been an advisor to numerous life science companies in both therapeutic and other bioscience applications. His formal training includes a medical degree from Queen's University, and post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for 30 years. Duyuru • Dec 08
Gemina Laboratories Ltd. (CNSX:GLAB) acquired 19% stake in Rapivd Limited for £0.52 million. Gemina Laboratories Ltd. (CNSX:GLAB) acquired 19% stake in Rapivd Limited for £0.52 million on December 7, 2022. As for consideration, £259,259 was paid in cash and Gemina Laboratories Ltd. issued 1,086,956 common shares. Gemina Laboratories Ltd. also has the option to purchase the remaining 81% of the RAPIvD. In connection with the Transaction, Robert Porter, the Chief Executive Officer of RAPIvD has agreed to join the board of Gemina Laboratories Ltd. All Gemina Shares issued in exchange for RAPIvD Shares pursuant to the Transaction will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.
Gemina Laboratories Ltd. (CNSX:GLAB) completed the acquisition of Rapivd Limited On December 7, 2022. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman John Davies was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Nov 12
Gemina Laboratories Ltd., Annual General Meeting, Jan 12, 2023 Gemina Laboratories Ltd., Annual General Meeting, Jan 12, 2023. Board Change • Aug 03
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Jul 12
Gemina Laboratories Ltd. announced that it has received CAD 0.92172 million in funding On July 11, 2022, Gemina Laboratories Ltd. closed the transaction. The company issued 1,536,200 units at a price of CAD 0.60 per unit for gross proceeds of CAD 921,720. Each unit will consist of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one share at an exercise price of CAD 0.80 per share until June 30, 2027, subject to acceleration in certain circumstances. In connection with the offering, the company issued 55,617 finder’s warrants and paid commissions of CAD 37,570.40. Each finder’s warrant will entitle the holder, on exercise thereof, to acquire one additional common share at a price of CAD 0.60 per common share until June 30, 2027. The securities issued in this private placement will be subject to a four month hold period expiring on November 11, 2022. Duyuru • Jul 01
Gemina Laboratories Ltd. has completed a Composite Units Offering in the amount of CAD 3.376041 million. Gemina Laboratories Ltd. has completed a Composite Units Offering in the amount of CAD 3.376041 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 5,626,735
Price\Range: CAD 0.6
Discount Per Security: CAD 0.042
Transaction Features: Regulation S; Rule 144A Duyuru • Jun 25
Gemina Laboratories Ltd. announced that it expects to receive CAD 1 million in funding Gemina Laboratories Ltd. announced a non-brokered private placement of up to 1,666,667 units at a price of CAD 0.60 per share for gross proceeds up to CAD 1,000,000 on June 23, 2022. Each unit will consist of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one share at an exercise price of CAD 0.80 per share for a period of 60 months following the Closing Date, subject to acceleration in certain circumstances. All securities issued as part of the transaction will be subject to a hold period four months. Duyuru • Jun 09
Gemina Laboratories Ltd. Appoints Brian Firth as Adviser Gemina Laboratories Ltd. appointed Brian Firth as an adviser to the Company. Brian Firth is a proven executive from the point-of-care diagnostics sector. He spent nearly eight years at Swiss Precision Diagnostics, initially as Managing Director of Swiss Precision Diagnostics' UK subsidiary, before becoming Chief Operating Officer of the parent company, Swiss Precisions Diagnostic GmbH. Swiss Precision Diagnostics is the manufacturer of the Clearblue family of pregnancy and fertility monitoring tests. At Swiss Precision, Brian was responsible for a broad range of business processes including quality management, HR, regulatory affairs, customer service and research leadership. Swiss Precision is jointly owned by Procter &Gamble and Abbott Laboratories. Prior to his time at Swiss Precision, Brian was a management consultant with Coopers and Lybrand working for a client roster that included Oxford Instruments, Johnson &Johnson, and Unilever. He subsequently established his own consultancy working with Inverness Medical, Agfa Healthcare, amongst others, before founding The Health Works Ltd. (a specialist operations consultancy) which was eventually sold to GE Healthcare. His career also includes time in the human wellness market, particularly human performance monitoring for applications in sports medicine and workplace diagnostics. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 03
Gemina Laboratories Ltd. Provides Technical Development Update for Initial Diagnostic Test Gemina Laboratories Ltd. provided recent development updates for its initial diagnostic test targeting the COVID-19 virus. Since achieving the previously announced design freeze stage of the Gemina COVID-19 test, preliminary cross-reactivity testing has been completed against seasonal human coronaviruses 229E, OC43, and NL63 as well as influenza A and B. The company to report that no cross-reactivity was observed for this panel of viruses in the preliminary study, providing confidence that the test will not provide a positive signal with viruses other than those associated with SARS-CoV-2. Additional testing has also been completed with a limited number of patient samples to assess performance against two regulated (commercial) antigen tests. The results were consistent between the Gemina C-19 test and the existing regulated tests, where it performed as well or better than the commercially available test. These independent studies on the Gemina test, post-design freeze, have brought to a successful conclusion the body of work on empirical validation required to complete the Phase 1 technical development program. The company remains on schedule with the three-month work program laid out in our previous technical update issued February 3, 2022. Upon completion of Phase 1, an initial feasibility lot of 746 Gemina COVID-19 antigen tests were manufactured for use in expanded prospective patient sample testing, as well as additional cross- reactivity and interfering substances testing. This initial manufacturing lot is a major milestone for the company, as it demonstrates the underlying novel chemistry platform can be produced at scale. The data from this next study will be incorporated into the Gemina COVID-19 test Information for Use ("IFU") documentation in preparation for a regulatory submission. Duyuru • Feb 25
Gemina Laboratories Ltd. Appoints David Browning as Head of Productization Gemina Laboratories Ltd. announced the appointment of David Browning as Head of Productization. David Browning has been an advisor to Gemina since 2020, and has been appointed to the role of Head of Productization and Director of Gemina Laboratories (UK) Limited. David started his career in vitro diagnostics training in clinical biochemistry in the UK National Health Service (NHS) before joining Amersham International. Board Change • Feb 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Feb 04
Gemina Laboratories Ltd. Announces Completion of Significant Development Step for Its SARS-COV-2 Rapid Test Gemina Laboratories Ltd. provided an update on its current activities related to the development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company's patented breakthrough chemistry platform. Following the previously announced prototype design freeze for use in saliva and the transfer of the prototype to International Point of Care (IPOC), the company announced the completion of another important milestone, namely: design freeze for shallownasal swab testing. From a regulatory perspective, nasal swabs have become the leading method for large scale rapid testing globally. Gemina's team previously announced that their SARS-CoV-2 test has already demonstrated outstanding performance in a lab setting. Independent laboratory results with Gemina's prototype SARS-CoV-2 rapid antigen test indicated the company was able to reliably detect recombinant SARS-CoV-2 nucleocapsid in saliva and nasal fluid samples with significantly higher sensitivity when compared with a panel of seven leading commercial rapid antigen tests. This latest milestone indicates that the performance of this finalized test design with inactivated virus and with real patient samples is sufficient evidence to initiate the production of three feasibility lots (of 3,500 rapid tests per lot) which will undergo third party performance evaluations. The test has been optimized for use with anterior (shallow) nasal swab samples in response to market and regulatory signals. Detection of inactivated virus in artificial nasal fluid at clinically relevant concentrations has been independently confirmed by an external laboratory using the Gemina test. A second independent evaluation is scheduled to occur within the next week. The test has also been run against nasal fluid provided from a panel of COVID-negative volunteers and shown to exhibit no non-specific binding (no false positive signals). In the following three months, the test will be taken through a series of sensitivity and specificity trials in advance of feasibility lot production, including evaluation of test specificity against seasonal coronaviruses. Three feasibility lots will then be tested to confirm sensitivity, usability, shelf stability, and lot-to-lot consistency with contrived inactivated virus samples. The test will then be subjected to an external performance evaluation with retrospective patient samples as part of the compilation of the data pack required to support regulatory submissions. Successful completion of these performance evaluations is a critical step towards manufacturing scale-up and allows the company to advance commercialization efforts through distribution and licensing agreements. Board Change • Jan 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.